Hepatology at the Congress decides how to treat viral hepatitis

Russian Congress «Hepatology Today", which became the 17th in a row, first appeared on the international level. The event, organized by the Russian Society for the Study of the Liver, was attended by more than 700 narrow specialists, 300 of which - Russian regional doctors. A key theme of the three-day meeting was to discuss the results of clinical trials for the treatment of chronic viral hepatitis.
This theme was interesting not only for hepatologists, but also for medical related specialties. The speakers at the symposium "Chronic viral hepatitis . What we have and what we want "were also infectious diseases, obstetrician-gynecologists and endocrinologists.

Professor A. Bueverov in its report "The place of interferon and ribavirin in the treatment of hepatitis C. The new predictors of sustained virologic response" presented the intermediate results of the Russian studies ML16709. He spoke about the high efficiency PEGASYS in clinical practice. The expert said that the combination of Pegasys and ribavirin is still the best treatment option for patients with hepatitis C, and noted that new therapies are not possible without the use of pegylated interferon and ribavirin.

Professor S. Mammaev, prepare an overview of the results of international studies on treatment   Chronic hepatitis and, in his scientific work, "Will there be a new era in the treatment of   Hepatitis C ? "Drew attention to the fact that the combination therapy of pegylated interferon and ribavirin for the treatment of Chronic Hepatitis   C in patients with genotype 1 virus predicts response to treatment depending on the type IL28V. Protease inhibitors of hepatitis C virus (boceprevir and telaprevir), according to experts, should not be used without pegylated interferon and ribavirin in hepatitis C therapy schemes
In addition, encouraging results Mamaev said application virus polymerase inhibitor (RG7128), as well as a new generation of protease inhibitors (danoprevir) in the treatment of chronic hepatitis C.

Industry News

Go back to the main page